<!DOCTYPE html><html prefix="og: http://ogp.me/ns#" lang="zh">
<!-- Mirrored from cn.nytimes.com/business/20131217/c17glaxo/zh-hant/dual/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:16:48 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head><meta charset="UTF-8"><!-- Browser render  --><meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"><meta name="renderer" content="webkit"><!-- End Browser render --><meta name="keywords" content=""><meta name="description" content="葛蘭素史克CEO本周一表示，公司不會再付費讓醫生推銷自己的產品，並將不再根據醫生開藥數量給予銷售代表報酬。"><meta id="uuid" name="uuid" content="e29ad00d44dfc910539215c4c669237c"><meta id="headline" name="headline" content="葛蘭素史克表示將停止給醫生付費 - 紐約時報中文網"><meta id="byline" name="byline" content="KATIE THOMAS"><meta id="date" name="date" content="2013-12-17T02:29:38.000Z"><link rel="alternate" href="../../index.html" hreflang="zh-Hans"><link rel="alternate" href="../index.html" hreflang="zh-Hant"><link rel="canonical" href="../index.html"><link rel="alternate" type="application/rss+xml" href="https://cn.nytimes.com/rss/zh-hant/"><meta name="apple-itunes-app" content="app-id=807498298, app-argument=nytimescn://article:e29ad00d44dfc910539215c4c669237c"><meta name="lang" property="lang" content="zh-cmn-hant"><!-- Apple IOS safari private meta --><link rel="apple-touch-icon-precomposed" sizes="144×144" href="../../../../../../static01.nyt.com/images/icons/ios-ipad-144x144.png"><link rel="apple-touch-icon-precomposed" sizes="114×114" href="../../../../../../static01.nyt.com/images/icons/ios-iphone-114x144.png"><link rel="apple-touch-icon-precomposed" href="../../../../../../static01.nyt.com/images/icons/ios-default-homescreen-57x57.png"><meta name="apple-mobile-web-app-title" content="葛蘭素史克表示將停止給醫生付費 - 紐約時報中文網"><meta name="apple-mobile-web-app-capable" content="yes"><!-- End Apple IOS safari private meta --><!-- Viewport and mobile --><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no,maximum-scale=1,minimum-scale=1,minimal-ui"><!-- End viewport and mobile --><meta http-equiv="Cache-Control" content="no-siteapp"><meta name="format-detection" content="telephone=no"><meta name="HandheldFriendly" content="true"><meta name="MobileOptimized" content="320"><meta name="x5-orientation" content="portrait"><meta name="full-screen" content="yes"><meta name="x5-fullscreen" content="true"><meta name="browsermode" content="application"><meta name="x5-page-mode" content="app"><meta name="msapplication-tap-highlight" content="no"><meta property="og:title" content="葛蘭素史克表示將停止給醫生付費"><meta property="og:type" content="article"><meta property="og:url" content="../index.html"><meta property="og:description" content="葛蘭素史克CEO本周一表示，公司不會再付費讓醫生推銷自己的產品，並將不再根據醫生開藥數量給予銷售代表報酬。"><meta property="og:site_name" content="紐約時報中文網"><meta property="article:publisher" content="https://www.facebook.com/nytimeschinese"><meta property="article:published_time" content="2013-12-17T02:29:38.000Z"><meta property="fb:pages" content="1504603339831430"><meta property="fb:app_id" content="853699254762608"><meta property="og:image" content="../../../../../../static01.nyt.com/images/2013/12/17/business/17glaxo/17glaxo-articleLarge.html"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:url" content="../index.html"><meta property="twitter:title" content="葛蘭素史克表示將停止給醫生付費"><meta property="twitter:description" content="葛蘭素史克CEO本周一表示，公司不會再付費讓醫生推銷自己的產品，並將不再根據醫生開藥數量給予銷售代表報酬。"><meta property="twitter:domain" content="cn.nytimes.com"><meta property="twitter:site" content="@nytchinese"><meta property="twitter:creator" content="@nytchinese"><meta property="twitter:image:src" content="../../../../../../static01.nyt.com/images/2013/12/17/business/17glaxo/17glaxo-articleLarge.html"><meta name="PT" content="article"><meta name="PST" content="News"><meta name="CG" content="business"><meta name="SCG" content=""><meta name="sourceApp" content="nyt-china-web"><meta name="ptime" content="20131217022938"><meta name="utime" content="20131217022938"><meta name="pdate" content="20131217"><meta name="dat" content="Dec. 17, 2013"><meta name="hdl" content="葛蘭素史克表示將停止給醫生付費"><meta name="byl" content="KATIE THOMAS"><meta name="lp" content="葛蘭素史克CEO本周一表示，公司不會再付費讓醫生推銷自己的產品，並將不再根據醫生開藥數量給予銷售代表報酬。"><link rel="shortcut icon" href="https://static01.nyt.com/favicon.ico"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/style-flex.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/web/style.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/article.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/slideshow/slideshow.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/cookie-banner/style.min619b.css?v=f1810d8"><title>葛蘭素史克表示將停止給醫生付費 - 紐約時報中文網</title></head><script>var js_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/js";
 var imgs_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style/imgs";
 var style_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style";
 var site = 1;
 var sectionName = "business";
 var adTyp = "art";
 var cookieString = {
     "title": "您的追蹤器設置",
     "headline": "我們使用 cookie 做什麼？",
     "summary": '<p>我們利用cookies和類似的技術識別您的重複訪問和偏好。我們還使用它們來衡量廣告系列的效果，定位廣告並分析和網站流量。更多關於cookies的資訊（包括如何停用），<a href="https://www.nytimes.com/zh-hant/privacy/cookie-policy" rel="noreferrer noopener" target="_blank" data-testid="GDPR-policy">請查看我們的「Cookie政策」</a>。</span><span>自2020年7月20日起，我們將根據您在我們服務中所訪問的內容類型向您顯示我們認為與您的興趣相關的廣告。您可以<a href="https://www.nytimes.com/zh-hant/privacy/cookie-policy#how-do-i-manage-trackers" rel="noreferrer noopener" target="_blank" data-testid="GDPR-objection">提出反對</a>。希望了解更多信息，請參見我們的<a href="https://nytimes.com/zh-hant/privacy/privacy-policy#we-allow-for-personalized-advertising-on-times-services" rel="noreferrer noopener" target="_blank" data-testid="GDPR-privacy">隱私政策</a>。</p><p>透過在此處點擊「我接受」或者「X」， 您將被視為同意使用cookies。您隨時可以通過我們的Cookie政策來更改您的跟踪器偏好。</p>',
     "button": "接受",
     "trackerButton": "您的追蹤器設置",
     "rejectButton": "拒絕所有",
     "lang": 'zh-hant',
     "trackerLink": "https://www.nytimes.com/zh-hant/privacy/cookie-policy",
 };
 var purrString = {
     "button": "請勿出售我的個人資訊",
     "snackbar": "你的設定已經保存在此瀏覽器和設備上。如果你清除了 cookie，這些設定也會被清除。",
     "snackbarError": "Something went wrong",
     "optedOutText": "我们不再出售您的個人資訊",
     "CFALinkText": "California Notices",
     "purrPopupTitle": "Your request to not sell your data will be stored for this browser and device",
     "purrPopupSummary": "If you clear your cookies, your preference will be forgotten. As a California resident, you have additional rights under the California Consumer Privacy Act of 2018. While The New York Times Company does not “sell” personal information of its readers as the term “sell” is traditionally understood, “sell” under the CCPA is broadly defined. To learn more, review the text below.",
     "purrPopupButton": "DISMISS",
     "purrPopupScrollContent": 'ssa sed. Nec sagittis aliquam malesuada bibendum arcu. Nunc sed blandit libero volutpat sed cras ornare arcu. Metus vulputate eu scelerisque felis imperdiet proin. Elit eget gravida cum sociis natoque penatibus. Sodales ut eu sem integer. Vitae auctor eu augue ut lectus arcu bibendum at. Vulputate ut pharetra sit amet aliquam id diam. Eu tincidunt tortor aliquam nulla facilisi cras fermentum odio eu. Imperdiet dui accumsan sit amet nulla facilisi morbi. Laoreet non curabitur gravida arcu ac tortor dignissim. Magna fringilla urna porttitor rhoncus dolor purus. In nulla posuere sollicitudin aliquam. At elementum eu facilisis sed odio. Diam in arcu cursus euismod quis viverra. Viverra suspendisse potenti nullam ac tortor vitae purus. Felis donec et odio pellentesque diam volutpat. Lacus sed turpis tincidunt id aliquet risus feugiat in.Aliquam ut porttitor leo a diam sollicitudin tempor',
     "lang": 'zh-hant'
 };
 cbSectionName = "business";
 cbByline = "KATIE THOMAS";</script><!-- Google Tag Manager --><script>(function(w,d,s,l,i){
     w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});
     var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';
     j.async=true;j.src='../../../../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;
     f.parentNode.insertBefore(j,f);
 })(window,document,'script','dataLayer','GTM-KTDZV8V');</script><!-- End Google Tag Manager --><!-- chartbeat --><script type="text/javascript">var _sf_startpt=(new Date()).getTime()</script><!-- /chartbeat --><body class="news"><main class="container-fluid main clearfix"><header class="row title-bar"><div class="nav-button default" id="menuBtn"><i class="icon-bars"></i></div><h1 class="logo"><a href="/"><svg role="img" aria-label="" width="90%" height="90%"><image width="100%" height="100%" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="/d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hant.svg" src="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hant%402x.png" alt="" border="0"></image></svg></a></h1><div class="nav-button default" id="gearBtn"><i class="icon-gear"></i></div><div class="popup gear-popup"><div class="tips-container"><div class="tips-border"></div><div class="tips-inner"></div></div><div class="popup-container"><div class="popup-body"><div class="setting-title">簡繁中文</div><div class="setting-option"><a href="../../index024e.html?changeLang=zh-hans">簡體 </a><a href="../../index27d8.html?changeLang=zh-hant" class="active">繁體</a></div><div class="setting-title">紐約時報 出版語言</div><ul class="menu-list"><li><a href="https://www.nytimes.com/">ENGLISH (英語)</a></li><li><a href="https://www.nytimes.com/es/">ESPAÑOL (西班牙語)</a></li></ul><div class="setting-title">字體大小</div><div class="setting-option"><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="small"> 小</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="normal" checked="checked"> 中</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="large"> 大</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="xlarge"> 超大</label></div></div></div></div></div></header><div class="top_banner_ad" id="topad" data-target="{&quot;pos&quot;:&quot;top&quot;,&quot;adv&quot;:&quot;&quot;}"></div><div class="article-area"><div class="setting-bar row"><div class="col-4 section-title"><h3>商業與經濟</h3></div><div class="col-8 setting-btns"><div class="row"><div class="col-6"><ul class="dual-btn"><li><a href="../../index.html"><span class="setting-btn-text">中文</span> <span class="setting-btn-text-mobile">中</span></a></li><li><a href="javascript:;" class="active"><span class="setting-btn-text">中英雙語</span> <span class="setting-btn-text-mobile">雙語</span></a></li><li><a href="#" target="_blank"><span class="setting-btn-text">英文 <i class="icon-share-square"></i> </span><span class="setting-btn-text-mobile">英</span></a></li></ul></div><div class="col-6 share-tools-top-container"><ul class="share-tools mobile-article"><li><a href="http://v.t.sina.com.cn/share/share.php?&amp;title=%E8%91%9B%E8%98%AD%E7%B4%A0%E5%8F%B2%E5%85%8B%E8%A1%A8%E7%A4%BA%E5%B0%87%E5%81%9C%E6%AD%A2%E7%B5%A6%E9%86%AB%E7%94%9F%E4%BB%98%E8%B2%BB&amp;url=https://cn.nytimes.com/business/20131217/c17glaxo/zh-hant/" target="_blank"><i class="icon-weibo"></i></a></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20131217/c17glaxo/zh-hant/" data-headline="%E8%91%9B%E8%98%AD%E7%B4%A0%E5%8F%B2%E5%85%8B%E8%A1%A8%E7%A4%BA%E5%B0%87%E5%81%9C%E6%AD%A2%E7%B5%A6%E9%86%AB%E7%94%9F%E4%BB%98%E8%B2%BB"> --><!-- <i class="icon-wechat"></i> --><!-- </a> --><!-- </li> --><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://cn.nytimes.com/business/20131217/c17glaxo/zh-hant/" trage="_blank"><i class="icon-facebook"></i></a></li><li><a href="https://plus.google.com/share?url=https://cn.nytimes.com/business/20131217/c17glaxo/zh-hant/" target="_blank"><i class="icon-google"></i></a></li><li><a href="https://twitter.com/share?text=%E8%91%9B%E8%98%AD%E7%B4%A0%E5%8F%B2%E5%85%8B%E8%A1%A8%E7%A4%BA%E5%B0%87%E5%81%9C%E6%AD%A2%E7%B5%A6%E9%86%AB%E7%94%9F%E4%BB%98%E8%B2%BB&amp;url=https://cn.nytimes.com/business/20131217/c17glaxo/zh-hant/" target="_blank"><i class="icon-twitter"></i></a></li><li><div class="line-it-button" data-lang="zh_Hant" data-type="share-g" data-url="https://cn.nytimes.com/business/20131217/c17glaxo/zh-hant/" style="display: none;"></div><script src="../../../../../../d.line-scdn.net/r/web/social-plugin/js/thirdparty/loader.min.js" async="async" defer="defer"></script></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20131217/c17glaxo/zh-hant/" data-headline="%E8%91%9B%E8%98%AD%E7%B4%A0%E5%8F%B2%E5%85%8B%E8%A1%A8%E7%A4%BA%E5%B0%87%E5%81%9C%E6%AD%A2%E7%B5%A6%E9%86%AB%E7%94%9F%E4%BB%98%E8%B2%BB"> --><!-- <i class="icon-qrcode"></i> --><!-- </a> --><!-- </li> --></ul><div class="share-btn"><i class="icon-forward"></i></div></div></div></div></div><article class="article-content article-dual font-normal"><div class="article-header"><header><small></small><h1>葛蘭素史克表示將停止給醫生付費</h1><h1 class="en-title">Glaxo Says It Will Stop Paying Doctors to Promote Drugs</h1></header><div class="byline-row"><div class="byline-box"><div class="byline"><address>KATIE THOMAS</address><time pudate="2013-12-17 02:29:38" datetime="2013-12-17 02:29:38">2013年12月17日</time></div><div class="share-btn"><i class="icon-forward"></i></div></div></div></div><div class="row"><section class="article-body"><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The British drug maker GlaxoSmithKline will no longer pay doctors to promote its products and will stop tying compensation of sales representatives to the number of prescriptions doctors write, its chief executive said Monday, effectively ending two common industry practices that critics have long assailed as troublesome conflicts of interest.</div></div><div class="col-lg-6"><div class="article-paragraph">英國製藥公司葛蘭素史克（GlaxoSmithKline，簡稱GSK）的首席執行官於本周一表示，公司不會再付費讓醫生推銷自己的產品，並將停止把銷售代表的報酬和醫生開藥數量掛鈎的做法。此舉將有效地制止兩種業內慣例，長期以來，批評者一直抨擊這些慣例帶來了不當利益衝突。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The announcement appears to be a first for a major drug company — although others may be considering similar moves — and comes at a particularly sensitive time for Glaxo. It is the subject of a bribery investigation in China, where authorities contend the company funneled illegal payments to doctors and government officials in an effort to boost drug sales.</div></div><div class="col-lg-6"><div class="article-paragraph">\r這似乎是主要的製藥公司首次發佈此類聲明——儘管其他公司可能也在考慮類似措施——出現在一個對GSK來說格外敏感的時期。在中國，GSK是一樁腐敗案的調查對象，當局指該公司暗地向醫生和政府官員支付非法酬金，以圖提升藥品銷售。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Andrew Witty, Glaxo’s chief executive, said in a telephone interview Monday that its proposed changes were unrelated to the investigation in China, and are part of a yearslong effort “to try and make sure we stay in step with how the world is changing,” he said. “We keep asking ourselves, are there different ways, more effective ways of operating than perhaps the ways we as an industry have been operating over the last 30, 40 years?”</div></div><div class="col-lg-6"><div class="article-paragraph">\rGSK首席執行官安偉傑(Andrew Witty)在周一的一次電話採訪中表示，公司提出的改進措施與在中國的調查無關，而是某個一年期措施的組成部分，目的是「嘗試確保我們跟上全球變化的潮流。我們不斷地追問自己，有沒有其他方法？跟也許可稱為製藥行業過去30到40年慣例的做法相比，有沒有更行之有效的運營方法？」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">For decades, pharmaceutical companies have paid doctors to speak on their behalf at conferences and other meetings of medical professionals, under the assumption that the doctors are most likely to value the advice of trusted peers.</div></div><div class="col-lg-6"><div class="article-paragraph">\r幾十年以來，製藥公司一直在給醫生付費，讓他們在醫學會議和其他醫藥界人士集會上為自己代言，因為他們認為，醫生最有可能看重有威望的同行的意見。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">But the practice has also been criticized by those who question whether it unduly influences the information doctors give each other and can lead them to prescribe drugs inappropriately to patients.</div></div><div class="col-lg-6"><div class="article-paragraph">\r不過，這種行為一直也受到一些人的質疑，這些人懷疑此舉不當地影響了醫生之間的信息交流，可能會導致他們給患者開出不當的處方藥物。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Under the plan, which Glaxo said would be completed worldwide by 2016, the company will no longer pay health care professionals to speak on its behalf about its products or the diseases they treat, “to audiences who can prescribe or influence prescribing,” it said in a statement. It will also stop providing financial support directly to doctors to attend medical conferences, a practice that is prohibited in the United States through an industry-imposed ethics code but still occurs in other countries. In China, authorities have said Glaxo compensated doctors for travel to conferences and lectures that never took place.</div></div><div class="col-lg-6"><div class="article-paragraph">\rGSK說，公司將在2016年之前在全球各地落實前述計劃。它在一份聲明中說，根據計劃，GSK不會再付費給醫務工作者，讓他們「在能夠開處方或影響處方決定的聽眾面前」為自己的產品或療效代言。公司還將停止直接贊助醫生參加醫學會議，美國已通過一項強制性的行業規範禁止了此類操作，但其他國家依然存在類似行為。在中國，當局已經表示，GSK曾給醫生提供差旅費，用於參加根本不存在的會議和講座。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Mr. Witty declined to comment on the Chinese investigation because he said it was still underway.</div></div><div class="col-lg-6"><div class="article-paragraph">\r安偉傑以調查仍在進行為由，拒絕對中方的調查置評。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Glaxo will continue to pay doctors consulting fees for market research because Mr. Witty said it was necessary for the company to gain insight from doctors about their products, but he said that activity would be limited in scope. A Glaxo spokesman said that each year the company spends “tens of millions” of dollars globally on the practices that it was ending, but declined to be more specific.</div></div><div class="col-lg-6"><div class="article-paragraph">\rGSK會繼續向醫生支付有關市場研究的諮詢費，安偉傑說，這是因為公司需要了解醫生對產品的看法，不過他說，這項活動會被限定在一定範圍之內。GSK的一名發言人說，公司每年都會為即將終止的此類做法在全球耗資「數千萬」美元，不過，他拒絕提供更詳盡的細節。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Glaxo is among the largest drug companies in the world, reporting global third-quarter sales of 6.51 billion pounds, or $10.1 billion, a 1 percent rise from the same period a year ago. Sales fell markedly in China as the investigation proceeded.</div></div><div class="col-lg-6"><div class="article-paragraph">\rGSK是全球最大的製藥公司之一，第三季度報告的全球銷售額達到65.1億英鎊，約合101億美元（約合613億元人民幣），比去年同期增長了1%。由於調查的推進，其在中國的銷售額出現了大幅下跌。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The move won qualified praise from Dr. Jerry Avorn, a professor of medicine at Harvard Medical School who has written critically about the drug industry’s marketing practices.</div></div><div class="col-lg-6"><div class="article-paragraph">\r此舉贏得了傑里·埃馮(Jerry Avorn)醫生有保留的稱讚，他是哈佛醫學院(Harvard Medical Schoolv)醫學教授，曾撰文批判製藥行業的市場營銷行為。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“It’s a modest acknowledgment of the fact that learning from a doctor who is paid by a drug company to give a talk about its products isn’t the best way for doctors to learn about those products,” Dr. Avorn said. But he noted that Glaxo would continue to provide what the company described in a statement as “unsolicited, independent educational grants” to continue educating doctors about their products.</div></div><div class="col-lg-6"><div class="article-paragraph">\r埃馮博士表示，「這相當於委婉地承認了一個事實，即對於醫生來說，了解產品的最佳途徑並不是聽那些收了製藥公司的錢來推廣產品的同行的介紹。」但他指出，GSK將繼續提供該公司在聲明中提到的「獨立培訓主動撥款」，繼續幫助醫生了解他們的產品。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">He said that in the past the grants had often been provided to for-profit companies that rely on such payments from drug companies, raising questions about whether they are providing truly independent information.</div></div><div class="col-lg-6"><div class="article-paragraph">\r他表示，過去，製藥公司經常會給一些營利性的公司提供此類款項，後者依賴這些資金生存，這樣的局面引發了人們的疑問，即它們提供的是不是真正獨立的信息。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Glaxo is first among its peers to announce a plan to end paid-speaker programs, but it is not the only company considering such a move, said Pratap Khedkar, who oversees the pharmaceutical practice at ZS Associates, a global sales and marketing firm.</div></div><div class="col-lg-6"><div class="article-paragraph">\r國際銷售營銷公司致盛諮詢公司(ZS Associates)負責審查製藥公司行為的普拉塔普·赫達卡(Pratap Khedkar)表示，GSK是第一個宣布終止僱傭代言人項目的製藥公司，但卻不是唯一的一個考慮此類措施的公司。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">He said a handful of drug makers were weighing similar actions for several reasons, including concerns about the reaction to the required disclosure of such payments that will begin next fall under a provision of the new health care law. Glaxo and several other major companies already report many such payments, but Mr. Khedkar said the new requirements may go farther than what some companies are reporting, and will be accessible on a searchable government website.</div></div><div class="col-lg-6"><div class="article-paragraph">\r他表示，其他一些製藥商也在考慮採取類似措施，原因擇多種多樣，比如擔心新醫改法的規定——明年秋天開始，他們必須公開此類款項——帶來的反應。GSK和其他幾家大型公司已經公布了很多相關信息，但赫達卡表示，新規定要求公開的信息可能遠多於一些公司彙報的內容，人們可以在一個可搜索政府網站上查到這些要求。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Previously, “It wasn’t really made public in some big, splashy way,” he said.</div></div><div class="col-lg-6"><div class="article-paragraph">\r他表示，以前，「這些信息並沒有以真正引人注目的方式公之於眾。」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Beginning in 2015, Glaxo will also no longer compensate sales representatives based on the number of prescriptions doctors write, a standard practice that some have said pushed pharmaceutical salespeople to inappropriately promote drugs to doctors. In 2012, Glaxo paid a record $3 billion fines to resolve charges that it had marketed best-selling antidepressants and other drugs for unapproved uses. It is one of several major drug companies to have settled such cases in recent years.</div></div><div class="col-lg-6"><div class="article-paragraph">\r從2015年開始，GSK將不再根據醫生開藥的數量來給予銷售代表報酬，一些人表示，這種業內慣例促使藥物銷售人員以不恰當的方式向醫生推廣藥物。2012年，GSK支付了30億美元的創紀錄罰款，以便解決相關指控，即該公司曾宣傳旗下最暢銷的抗抑鬱葯及其他一些藥物具有未經證實的療效。最近幾年，有幾家大型製藥公司解決了此類案件，GSK就是其中之一。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Glaxo said its sales representatives worldwide would instead be paid based on their technical knowledge, the quality of service they provided to clients to improve patient care, and the company’s business performance. The company made such changes in the United States in 2011 but will now extend the practices to its global business.</div></div><div class="col-lg-6"><div class="article-paragraph">\rGSK表示，該公司將根據銷售代表的技術知識、為客戶提供的改進治療效果的服務的質量及公司業績來為世界各地的銷售代表支付薪酬。GSK於2011年在美國進行了此類改革，目前則打算將此類舉措延伸到全球業務當中。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Mr. Khedkar said some other companies are also experimenting with different ways to compensate sales representatives, but they must tread carefully.</div></div><div class="col-lg-6"><div class="article-paragraph">\r赫達卡表示，其他一些公司也在嘗試根據不同標準為銷售代表提供薪酬，但它們必須格外小心。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“You remove the incentive to do anything inappropriate, but you also remove the incentive to do what is appropriate, which is to promote the on-label use of your product,” he said.</div></div><div class="col-lg-6"><div class="article-paragraph">\r他說，「你消除了做不該做的事情的動機，但卻同時消除了做該做的事情的動機，該做的事情就是推廣對產品的合理使用。」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Mr. Witty said the experience in the United States had been positive and had improved relationships with doctors and medical institutions.</div></div><div class="col-lg-6"><div class="article-paragraph">\r安偉傑表示，在美國進行的嘗試帶來了積極的效果，改善了公司與醫生和醫療機構的關係。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“It has really allowed us to build an engagement which is more substantive than it used to be, and it’s good for everybody,” he said.</div></div><div class="col-lg-6"><div class="article-paragraph">\r他表示，「這真的讓我們建立了一種比過去更具實質意義的關係，對大家來說都是好事情。」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Dr. Raed Dweik, the new chairman of the innovation management and conflict of interest committee at the Cleveland Clinic, said he hoped other companies would follow suit.</div></div><div class="col-lg-6"><div class="article-paragraph">\r克利夫蘭醫學中心(Cleveland Clinic)創新管理與利益衝突委員會的新任主席拉伊德·德維克(Raed Dweik)博士表示，他希望其他公司效仿GSK的做法。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“As a physician, I periodically meet with these sales reps and they usually come in armed with information about me that I don’t even know,” he said, like the number of prescriptions he writes for the drug company’s product. “I feel that’s not really a comfortable interaction to have.”</div></div><div class="col-lg-6"><div class="article-paragraph">\r「作為一名醫生，我常常見到這些銷售代表，他們來的時候通常已經對我了如指掌，有些信息連我自己都不知道，」他說，例子就是他為製藥公司產品開出的處方數量。「我覺得，這並不是一種讓人愜意的互動。」</div></div></div></div><div class="article-body-aside col-lg-3"></div></div></section></div><div class="col-lg-12 row author-info-container"><footer class="author-info"><p>翻譯：張薇、許欣</p></footer></div></article><div class="container article-footer"><div class="row"><div class="col-lg-12 dual-refer-cont"><div class="related-cont"><h4>相關報導</h4><ul class="refer-list"><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/world/20131024/c24glaxo/zh-hant/" title="葛蘭素史克因中國銷量暴跌受重創"><div><h3 class="refer-list-headline">葛蘭素史克因中國銷量暴跌受重創</h3><p class="refer-pubdate">2013年10月24日</p></div></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../../20130822/c22consultants/zh-hant/index.html" title="英國顧問在滬被捕，或涉葛蘭素案"><div><h3 class="refer-list-headline">英國顧問在滬被捕，或涉葛蘭素案</h3><p class="refer-pubdate">2013年8月22日</p></div></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20130805/cc05gsk/zh-hant/" title="解讀葛蘭素史克公司被查原因"><div><h3 class="refer-list-headline">解讀葛蘭素史克公司被查原因</h3><p class="refer-pubdate">2013年8月5日</p></div><img alt="解讀葛蘭素史克公司被查原因" src="../../../../../../static01.nyt.com/images/2013/07/29/business/dealbook/dbpix-glaxo-china/dbpix-glaxo-china-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../../20130725/c25glaxo/zh-hant/index.html" title="葛蘭素總裁回應公司在華賄賂醜聞"><div><h3 class="refer-list-headline">葛蘭素總裁回應公司在華賄賂醜聞</h3><p class="refer-pubdate">2013年7月25日</p></div><img alt="葛蘭素總裁回應公司在華賄賂醜聞" src="../../../../../../static01.nyt.com/images/2013/07/25/business/global/25glaxo/25glaxo-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../../20130722/c22drugs/zh-hant/index.html" title="葛蘭素史克行賄案或涉更多製藥商"><div><h3 class="refer-list-headline">葛蘭素史克行賄案或涉更多製藥商</h3><p class="refer-pubdate">2013年7月22日</p></div><img alt="葛蘭素史克行賄案或涉更多製藥商" src="../../../../../../static01.nyt.com/images/2013/07/22/business/drug/drug-thumbLarge.html" width="75" height="75"></a></div></li></ul></div></div><div class="col-lg-12"><div class="related hot_article"><h5 class="related-title">最受歡迎</h5><ol class="related-articles"><li><a href="#https://cn.nytimes.com/usa/20220127/computer-chip-shortage-taiwan/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>戰棋推演報告稱台灣半導體工廠停產可能引發中美衝突</h4><img alt="戰棋推演報告稱台灣半導體工廠停產可能引發中美衝突" src="../../../../../../static01.nyt.com/images/2022/01/26/us/politics/26dc-wargames/merlin_177315390_5fcf8532-e370-4f81-8f99-45c6c83044f4-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/pakistan-united-states-china/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>「巴鐵」軍方為什麼想與中國保持距離？</h4><img alt="「巴鐵」軍方為什麼想與中國保持距離？" src="../../../../../../static01.nyt.com/images/2022/01/24/opinion/21Rafiq1/21Rafiq1-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220126/china-covid-19/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>中國追求「清零」將把國家置於災難之中</h4><img alt="中國追求「清零」將把國家置於災難之中" src="../../../../../../static01.nyt.com/images/2022/01/25/opinion/25emanuel/25emanuel-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/sports/20220127/peng-shuai-china-australian-open/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>澳網再現「彭帥在哪裡」：球員和觀賽者拒絕遺忘、為其發聲</h4><img alt="澳網再現「彭帥在哪裡」：球員和觀賽者拒絕遺忘、為其發聲" src="../../../../../../static01.nyt.com/images/2022/01/26/sports/26aus-china1/merlin_199503951_9c695f25-2b8e-41b4-9c97-bf91de7aa190-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220125/gang-chen-mit-china/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>「我們在殘害我們自己」：華裔教授陳剛案背後的憤怒與幻滅</h4><img alt="「我們在殘害我們自己」：華裔教授陳剛案背後的憤怒與幻滅" src="../../../../../../static01.nyt.com/images/2022/01/24/science/24CHEN-promo/24CHEN-promo-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/virtual-reality-simulation/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>你可以開始相信，我們有可能會活在虛擬現實裡</h4><img alt="你可以開始相信，我們有可能會活在虛擬現實裡" src="../../../../../../static01.nyt.com/images/2022/01/26/opinion/26manjoo-image/26manjoo-image-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/winter-olympics-china-beijing-xi-jinping/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>不再取悅世界：一屆展現習近平全面願景的冬奧會</h4><img alt="不再取悅世界：一屆展現習近平全面願景的冬奧會" src="../../../../../../static01.nyt.com/images/2022/01/13/world/00xi-olympics-30/00xi-olympics-30-thumbLarge.jpg"></article></a></li><li><a href="../../../../20220126/imf-world-economic-report/zh-hant/indexf61c.html?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>國際貨幣基金組織稱中美經濟放緩將拖累全球經濟</h4><img alt="國際貨幣基金組織稱中美經濟放緩將拖累全球經濟" src="../../../../../../static01.nyt.com/images/2022/01/25/multimedia/25global-econ-brf/25global-econ-brf-thumbLarge-v2.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/asia-pacific/20220126/north-korea-launches-missiles-kim/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>朝鮮突然頻繁試射導彈傳遞了什麼信息？</h4><img alt="朝鮮突然頻繁試射導彈傳遞了什麼信息？" src="../../../../../../static01.nyt.com/images/2022/01/21/world/00nkorea-gameplan-01/00nkorea-gameplan-01-thumbLarge.html"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/china-zero-covid-policy/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>多地封鎖引發沮喪與抱怨，中國「清零」政策還能走多遠？</h4><img alt="多地封鎖引發沮喪與抱怨，中國「清零」政策還能走多遠？" src="../../../../../../static01.nyt.com/images/2022/01/20/world/00virus-china-lockdown-01/00virus-china-lockdown-01-thumbLarge.html"></article></a></li></ol></div></div></div></div></div><footer class="row copy-footer">&copy; 2022 The World Economy Observer.<ul class="footerLinkList"><li class="footerLink"><a rel="nofollow" href="/ad/">广告</a></li><li class="footerLink"><a rel="nofollow" href="/about-us/">关于我们</a></li><li class="footerLink"><a rel="nofollow" href="/contact/">联系我们</a></li><li class="footerLink"><a rel="nofollow" href="/tos/">服务条款</a></li><li class="purr-content"></li></ul></footer><script src="../../../../../../d1f1eryiqyjs0r.cloudfront.net/js/libs/require619b.js?v=f1810d8"></script><script src="../../../../../../d1f1eryiqyjs0r.cloudfront.net/js/web/article.min619b.js?v=f1810d8"></script></main></body>
<!-- Mirrored from cn.nytimes.com/business/20131217/c17glaxo/zh-hant/dual/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:16:48 GMT -->
</html>